Plenary speaker

Prof Dr Owen Woodman

RMIT, Australia

Owen Woodman has a BSc (Hons) (1974) and PhD (1981) from the University of Melbourne. He has more than 30 years’ experience in research into the function of the cardiovascular system and the adverse effects of disease, working at institutions including Harvard University and the University of Melbourne (Departments of Pharmacology, Physiology and Medicine [Austin Hospital]) before joining RMIT University in 2007 where he was Professor of Cell Biology and Head of the Discipline of Cell Biology and Anatomy in the School of Health & Biomedical Sciences until March 2018. He is now an Honorary Professorial Fellow in the Heart Failure Pharmacology group at the Baker Heart & Diabetes Institute. He has a particular interest in the development of new drugs for the treatment of acute myocardial infarction and vascular disease, including diabetes-induced vascular pathologies and has published 135 papers on cardiovascular physiology and pharmacology. He is one of the inventors on several patents relating to synthetic flavonols for the treatment of cardiovascular disease. His work in conjunction with colleagues from the Howard Florey Institute and the School of Chemistry, University of Melbourne has formed the basis of work towards the commercial development of cardioprotective drugs by the biotechnology company Armaron Bio Pty Ltd ( for which he is the Chief Scientific Officer.